(S) -2-(Boc-Amino) neo-8-Enoic Acid CAS 300831-21-4 Purity> 98.0% (GC) ee > 99.0% Factaraidh Eadar-mheadhanach Paritaprevir

Tuairisgeul goirid:

Ainm: (S) -2-(Boc-Amino) non-8-Enoic Acid

CAS: 300831-21-4

Purity: > 98.0% (GC)

ee:> 99.0%

Coltas: Brown Liquid

Eadar-mheadhanach Paritaprevir (CAS: 1216941-48-8)

E-Mail: alvin@ruifuchem.com

Cuir post-d thugainn

Mion-fhiosrachadh toraidh

Bathar Co-cheangailte

Bathar Tags

Tuairisgeul:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

Feartan ceimigeach:

Ainm Ceimigeach	(S) -2-(Boc-Amino) neo-8-Enoic Acid
Co-fhaclan	(S) -2-(tert-Butoxycarbonylamino) non-8-Enoic Acid;(S)-2-(Boc-Amino)-8-Nonenoic Acid;(2S) -2-[(2-Methylpropan-2-yl)oxycarbonylamino] neo-8-Enoic Acid;(2S)-2-{[(tert-Butoxy)carbonyl] amino} neo-8-Enoic Acid
Àireamh CAS	300831-21-4
Àireamh CAT	RF-CC347
Inbhe Stoc	Anns a’ bhùth
Foirmle Molecular	C14H25NO4
Cuideam Molecular	271.35
Dùmhlachd	1.035 ± 0.06 g / cm3
Brand	Ceimigeach Ruifu

Sònrachaidhean:

Nì	Sònrachaidhean
Coltas	Liath Dhonn
Purity / Modh Mion-sgrùdadh	>98.0% (GC)
ee	> 99.0%
Inbhe deuchainn	Inbhe Iomairt
Cleachdadh	Eadar-mheadhanach Paritaprevir (CAS: 1216941-48-8)

Pacaid & Stòradh:

Pacaid: Botal fluorinated, 25kg / Drum, no a rèir riatanas luchd-ceannach

Suidheachadh stòraidh:Bùth ann an soithichean dùinte ann an àite fionnar is tioram;Dìon bho sholas is taiseachd

Buannachdan:

Ceistean Cumanta:

Iarrtas:

(S) -2-(Boc-Amino) non-8-Enoic Acid (CAS: 300831-21-4) a chleachdadh mar eadar-mheadhanach ann an synthesis Paritaprevir (CAS: 1216941-48-8) agus analogs co-cheangailte.Tha Paritaprevir na neach-dìon protease NS3 / 4A an dàrna ginealach, na phàirt den leigheas measgachadh bhìoras hepatitis C làn-bheòil, gun interferon a chaidh a leasachadh le Enanta Pharmaceuticals agus AbbVie.Chaidh an clàr dòs stèidhichte de Paritaprevir, Ombitasvir agus Ritonavir a chaidh a ghabhail còmhla ri Dasabuvir aontachadh airson làimhseachadh genotype 1 HCV cronach anns na SA agus an EU ann an 2014, agus chaidh aontachadh a bharrachd airson làimhseachadh galar HCV leantainneach genotype 4 gun cirrhosis leis na SA FDA ann an 2015.